Groundbreaking Drug Launches
Paltusotine (Palsonify)
Mechanism of Action: Somatostatin receptor 2 agonists Drug class: Small molecules Originator: Crinetics Pharmaceuticals
Launched date: October 2025 (USA) Indication: Acromegaly
Trials: PATHFNDR-1 and PATHFNDR-2
Acromegaly
Acromegaly is a rare endocrine disorder in adults characterized by abnormal enlargement of bones, organs, and soft tissues. It is caused by excess production of growth hormone from the pituitary gland, which in turn raises insulin-like growth factor-1 levels. In most cases, the condition results from a benign tumor of the pituitary gland.
How Acromegaly Impacts the Body
Excess growth hormone (GH) and IGF-1 affect multiple organs and systems, beyond the visible physical changes:
- Dental Health: Acromegaly can enlarge the jaw and create gaps between teeth, alter bite alignment, and enlarge the tongue, which may affect speech and breathing. Regular dental care is crucial to manage these changes.
- Reproductive and Sexual Health: Hormonal imbalances from high GH can lead to reduced libido, low testosterone, and erectile dysfunction in men. Soft tissue enlargement may occur, but sexual issues are primarily hormonal.
- Voice Changes: Thickening of the vocal cords and throat tissues can deepen or hoarsen the voice over time. Snoring and altered speech patterns may also develop.
Treatment challenges Treating acromegaly is challenging due to often late diagnosis, which can result in severe comorbidities such as cardiovascular disease and diabetes. Achieving a complete surgical cure can be difficult for large tumors, and medical treatments like somatostatin analogues may face resistance. Additional hurdles include potential side effects from radiation (e.g., hypopituitarism), ongoing sleep apnea, and the emotional and psychological burden of the disease. Effective management requires complex, lifelong, multimodal care to control symptoms, prevent complications, and enhance quality of life.
Why is Paltusotine poised to make an impact in 2026?
Paltusotine (Palsonify) is an orally bioavailable, non-peptide somatostatin receptor 2 (SST2) agonist developed by Crinetics Pharmaceuticals for the treatment of acromegaly and carcinoid syndrome. Palsonify is set to make a notable impact in 2026 following its FDA approval for acromegaly in late 2025. The drug is gaining strong commercial momentum, with plans to expand into carcinoid syndrome and a European market review targeting potential approval by mid-2026, positioning it as a leading oral therapy.
Analyst revenue projections for 2026 vary, reflecting the recent launch and market dynamics:
- Crinetics Guidance: The company expects around $45 million in revenue.
- JMP Securities: Following a higher-than-anticipated annual price, JMP raised its 2026 estimate to roughly $100 million.
- Broader Analyst Outlook: Firms like Piper Sandler project peak sales could reach $1.5 billion by 2030, indicating substantial long-term growth potential.
Regulatory milestones for Paltusotine
Registrational Trials
The U.S. Food and Drug Administration (FDA) pproved PALSONIFY for the treatment of for the Treatment of Acromegaly in Adults, supported by the data from PATHFNDR-1 and PATHFNDR-2 clinical trials.
PATHFNDR-1:
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (NCT04837040).
“The PATHFNDR-1 trial demonstrated that PALSONIFY effectively maintained biochemical and symptomatic control in acromegaly patients transitioning from injectable therapies, with a significant proportion achieving normal IGF-1 levels compared to placebo”
“The PATHFNDR-2 trial confirmed PALSONIFY’s efficacy, with a majority of acromegaly patients achieving normal IGF-1 levels and symptom improvement, supporting its FDA approval as the first daily oral treatment.”
PATHFNDR-2:
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (NCT05192382).
